Share on StockTwits

Analysts at Leerink Swann initiated coverage on shares of Loxo Oncology (NASDAQ:LOXO) in a research report issued to clients and investors on Tuesday. The firm set an “outperform” rating and a $20.00 price target on the stock. Leerink Swann’s target price would suggest a potential upside of 53.73% from the company’s current price.

Other equities research analysts have also recently issued reports about the stock. Analysts at Oppenheimer initiated coverage on shares of Loxo Oncology in a research note on Tuesday. They set an “outperform” rating and a $20.00 price target on the stock. Separately, analysts at Cowen and Company initiated coverage on shares of Loxo Oncology in a research note on Tuesday. They set an “outperform” rating on the stock. Finally, analysts at Stifel Nicolaus initiated coverage on shares of Loxo Oncology in a research note on Tuesday. They set a “buy” rating and a $20.00 price target on the stock. Five analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus price target of $20.75.

Loxo Oncology (NASDAQ:LOXO) opened at 13.01 on Tuesday. Loxo Oncology has a 52-week low of $12.687 and a 52-week high of $13.42. The stock’s 50-day moving average is $13.03 and its 200-day moving average is $13.03. The company’s market cap is $207.4 million.

Loxo Oncology, Inc (NASDAQ:LOXO) develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.